XOFIGO
Active Ingredient: RADIUM RA-223 DICHLORIDE
Product Overview
About XOFIGO
XOFIGO is a prescription medication containing the active ingredient Radium Ra-223 dichloride, a radioactive isotope used in the treatment of certain types of bone metastases.
Key Benefits & Uses
- Treatment of castration-resistant prostate cancer (CRPC) with bone metastases
- Relief of bone pain associated with CRPC and bone metastases
- Delay in the time to first skeletal-related event (SRE) in patients with CRPC and bone metastases
Active Ingredient & Action
Radium Ra-223 dichloride is a radioactive isotope that selectively targets and destroys cancer cells in the bone, reducing bone pain and delaying the progression of bone metastases. It works by emitting alpha particles that damage the DNA of cancer cells, ultimately leading to cell death.
Important Notes
XOFIGO is a radioactive medication that requires special handling and administration. Patients should be advised to follow the instructions provided by their healthcare provider and to take the medication exactly as directed. Common side effects may include nausea, diarrhea, and fatigue. Patients should also be aware of the potential risks associated with radiation exposure, including the possibility of secondary cancers and radiation-induced bone marrow failure.
Visitor ratings
Help others by rating how useful this product page is.
No ratings yet — be the first.
